All News
Filter News
Found 500,980 articles
-
Novartis announced that John Tsai, formerly of Amgen, is joining the company as Head of Global Drug Development and chief medical officer.
-
Shares of Novartis are down nearly 3 percent this morning after the company reported a sharp decline in generic drugs and sales results from key branded medicines that missed analysts’ projections for the first quarter.
-
The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Tagrisso (osimertinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) in tumors with epidermal growth factor receptor (EGFR) mutations.
-
Pfizer’s consumer health business has been spurned again. This time by mega-consumer goods company Proctor & Gamble. which opted today to acquire Germany-based Merck KGaA’s consumer health unit for $4.2 billion.
-
With the cutting of a ribbon more than 200 new jobs are expected to be created as China-based WuXi AppTec officially opened its expanded Laboratory Testing Division (LTD) facility in New Jersey.
-
Many scientists spend countless hours applying for full-time positions at colleges and universities only to experience the sting of rejection. Overall, less than half of life science professionals with doctorate degrees work in academia.
-
Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique combination antibiotic therapy - effective against the WHO Critical Priority Carbapenem resistant bacterial pathogens
4/19/2018
Helperby also presented preclinical data which shows that AZT is active against carbapenem and colistin resistant Enterobacteriaceae. AZT is a DNA chain terminator and represents a new class of antibacterial agent against the most resistant Gram-negative bacteria. Further data were presented showing the combination to be active in animal models.
-
MOLOGEN Presented Strong EnanDIM® TME Data at AACR 2018
4/19/2018
The biopharmaceutical company MOLOGEN AG presented data of its EnanDIM® molecules, a new generation of potent non chemically-modified TLR9 agonists, at the AACR Annual Meeting 2018 (American Association for Cancer Research) in Chicago, Illinois, U.S. (14 – 18 April 2018).
-
Revance Investor Day Highlights New Neuroscience Indications in Development
4/19/2018
- Lead product for treatment of glabellar lines on track to report SAKURA Phase 3 open-label safety results in second half of 2018 - - Initiating Phase 3 pivotal trial for cervical dystonia in current quarter - - Company to add RT002 clinical programs in adult upper limb spasticity and chronic migraine -
-
QIAGEN posts 2017 Annual Report on Its website
4/19/2018
QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) announced today that has posted its 2017 Annual Report on its website at http://financialreport.qiagen.com.
-
Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders
4/19/2018
Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 9:00 a.m. (Eastern Daylight Time) on Thursday, April 26, 2018.
-
Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership
4/19/2018
Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines.
-
Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region
4/19/2018
Tocagen eligible to receive up to $127 million in upfront payment, development and commercial milestones, plus additional double-digit tiered sales royalties; Upfront and near-term development milestones payments total up to $20 million
-
Sensus Healthcare Expands International Business to Meet Rising Patient Demand for Non-Invasive Skin Cancer and Keloid Treatments
4/19/2018
EVP Rick Golin Assumes New Role Bringing Superficial Radiation Therapy to International Distributors in Asia, the Americas, Europe and the Middle East
-
Neogen names Donofrio VP of Food Safety R&D
4/19/2018
Neogen Corporation (NASDAQ: NEOG) announced today that it had named Dr. Robert Donofrio as Vice President of Food Safety Research and Development.
-
TESARO to Receive 2018 Partnership Award at CancerCare® Gala
4/19/2018
CancerCare®, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, announced that TESARO will receive their 2018 Partnership Award.
-
Neuropeptide Y Y1 receptor Structures Offer New Opportunities for Anti-obesity Drug Discovery
4/19/2018
-Structures of human neuropeptide Y receptor Y1R reveal drug recognition mechanisms
-
Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting
4/19/2018
Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 1 safety and tolerability data of single ascending doses of CNTX-6970 in healthy volunteers and Phase 2b efficacy and safety data of CNTX-4975 for the treatment of moderate to severe osteoarthritis knee pain at the 34th Annual American Academy of Pain Medicine (AAPM) Meeting
-
Celgene Corporation Announces Changes to Its Board of Directors
4/19/2018
Gilla Kaplan, Ph.D., retiring from Board of Directors after 20 years of service US health insurance expert Patricia Hemingway Hall elected to Board of Directors Juno Therapeutics co-founder and former CEO Hans Bishop elected to Board of Directors
-
ZS Teams Up with Valkre Solutions to Enhance Its Key Account Management Offering
4/19/2018
Partnership Will Help Clients Develop and Enable Strategic Relationships with Key Accounts